Sensei Biotherapeutics (SNSE) Competitors $7.65 -0.30 (-3.77%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNSE vs. NBRV, APLT, PLUR, PRLD, MURA, ATNM, SCLX, GRCE, XCUR, and ACRVShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Nabriva Therapeutics (NBRV), Applied Therapeutics (APLT), Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), Scilex (SCLX), Grace Therapeutics (GRCE), Exicure (XCUR), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. Its Competitors Nabriva Therapeutics Applied Therapeutics Pluri Prelude Therapeutics Mural Oncology Actinium Pharmaceuticals Scilex Grace Therapeutics Exicure Acrivon Therapeutics Sensei Biotherapeutics (NASDAQ:SNSE) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation. Do analysts rate SNSE or NBRV? Sensei Biotherapeutics currently has a consensus target price of $90.00, indicating a potential upside of 1,076.47%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is SNSE or NBRV more profitable? Sensei Biotherapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Sensei Biotherapeutics' return on equity of -66.72% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sensei BiotherapeuticsN/A -66.72% -57.10% Nabriva Therapeutics -148.11%-365.53%-135.81% Does the media prefer SNSE or NBRV? In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Sensei Biotherapeutics and 0 mentions for Nabriva Therapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Nabriva Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Sensei Biotherapeutics Very Positive Nabriva Therapeutics Neutral Do insiders & institutionals believe in SNSE or NBRV? 10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher earnings & valuation, SNSE or NBRV? Sensei Biotherapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.33Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Which has more risk & volatility, SNSE or NBRV? Sensei Biotherapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. SummarySensei Biotherapeutics beats Nabriva Therapeutics on 12 of the 16 factors compared between the two stocks. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.65M$2.92B$5.51B$9.39BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.3320.5428.2719.87Price / SalesN/A258.87424.8998.56Price / CashN/A42.3835.5357.53Price / Book0.257.768.215.70Net Income-$30.16M-$55.11M$3.24B$257.71M7 Day Performance-15.93%1.94%0.43%0.89%1 Month Performance16.79%12.55%7.84%11.09%1 Year Performance-45.55%0.64%28.19%16.58% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.7506 of 5 stars$7.65-3.8%$90.00+1,076.5%-43.1%$9.65MN/A-0.3340Positive NewsGap DownNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070APLTApplied Therapeutics4.5491 of 5 stars$0.34+4.9%$6.10+1,717.6%-92.2%$45.30M$460K-0.7830Positive NewsPLURPluri3.2922 of 5 stars$5.79+0.2%$12.00+107.3%-13.7%$45.28M$330K-1.05150Gap DownPRLDPrelude Therapeutics3.7073 of 5 stars$0.81+1.6%$4.50+457.8%-86.8%$44.82M$7M-0.48120Positive NewsMURAMural Oncology3.4426 of 5 stars$2.48-3.9%$12.00+383.9%-28.4%$44.55MN/A-0.32119Positive NewsATNMActinium Pharmaceuticals2.8357 of 5 stars$1.42-1.4%$4.00+181.7%N/A$44.30MN/A-1.0230Positive NewsSCLXScilex2.5614 of 5 stars$6.25-1.7%$455.00+7,180.0%-89.8%$44.21M$50.71M-0.2280Positive NewsGap UpGRCEGrace Therapeutics2.5554 of 5 stars$3.00-4.2%$12.00+300.0%N/A$43.28MN/A-3.37N/AGap DownXCURExicure1.3426 of 5 stars$6.47-4.6%N/A+1,926.0%$42.83M$500K-1.6950Positive NewsACRVAcrivon Therapeutics3.8097 of 5 stars$1.25-3.1%$17.71+1,317.1%-83.6%$40.45MN/A-0.5658Positive News Related Companies and Tools Related Companies NBRV Alternatives APLT Alternatives PLUR Alternatives PRLD Alternatives MURA Alternatives ATNM Alternatives SCLX Alternatives GRCE Alternatives XCUR Alternatives ACRV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNSE) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
